Sign Up Today and Learn More About Thrive Earlier Detection Stock
Invest in or calculate the value of your shares in Thrive Earlier Detection or other pre-IPO companies through EquityZen's platform.
Thrive Earlier Detection Stock
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care.
About Thrive Earlier Detection Stock
Founded
2019
Headquarters
Cambridge, MA, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences and Gamma3.
Thrive Earlier Detection Management
Leadership team at Thrive Earlier Detection
Chief Commercial Officer
Matt Franklin
Founder
Kenneth Kinzler
Join now and verify your accreditation status to gain access to:
- Thrive Earlier Detection Current Valuation
- Thrive Earlier Detection Stock Price
- Thrive Earlier Detection Management
- Available deals in Thrive Earlier Detection and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Thrive Earlier Detection Cap Table and Funding History by Share Class and Liquidity Preferences
- Thrive Earlier Detection Revenue and Financials
- Thrive Earlier Detection Highlights
- Thrive Earlier Detection Business Model
- Thrive Earlier Detection Risk Factors
- Thrive Earlier Detection Research Report from SACRA Research
Trading Thrive Earlier Detection Stock
How to invest in Thrive Earlier Detection stock?
Accredited investors can buy pre-IPO stock in companies like Thrive Earlier Detection through EquityZen funds. These investments are made available by existing Thrive Earlier Detection shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Thrive Earlier Detection stock?
Shareholders can sell their Thrive Earlier Detection stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."